327 Drug Products to Enter China’s 7th Round of Volume-based Procurement (VBP)
On July 13, the National Joint Drug Procurement Office announced the preliminary result for the bid of the 7th round of volume-based procurement (VBP). 327 products (61 drugs if differentiated by active ingredients) owned by 217 companies won the bid in the preliminary stage.
The bid-winning products cover 31 disease categories, including common and/or chronic diseases such as hypertension, diabetes, gastrointestinal disorders and severe diseases of lung/liver/kidney/colon cancer.
The bid-winning products’ prices were reduced by 48% on average. In terms of kidney cancer drugs, the average price of Lenvatinib Mesilate Capsules was cut by 83.33% from 108 yuan/capsule to 18 yuan/capsule. Among drugs for treating high blood pressure, Nifexdipine Controlled-release Tablets’ average price dropped by 58% and Metoprolol Succinate Sustained-Release Tablets’ by 53%.
Of the 327 products, six are from international pharma companies and their VBP prices are listed below.
| Drug Product | Specification | Company | VBP Price |
| Oseltamivir Phosphate Capsules | 75mg*10 capsules per blister pack in each box | Hetero Labs Limited | 16.50 yuan/box |
| Iopamidol Injection | 100ml: 37g(I)*10 bottles in each box | Shanghai Bracco Sine Pharmaceutical Industry Co., Ltd. | 1,192.79 yuan/box |
| Ebastine Tablets | 10mg*10 tablets per blister pack in each box | Almirall, S.A. (Industrias Farmaceuticas Almirall, S.A.) | 3.49 yuan/box |
| Ezetimibe Tablets | 10mg*30 tablets in each box | Sandoz Inc. (Lek Pharmaceuticals d.d.) | 38.89 yuan/box |
| Micafungin Sodium for Injection | 50mg*1 bottle in each box | Astellas Pharma Europe B.V. (Astellas Pharma Tech Co., Ltd. Takaoka Plant) | 86.81 yuan/box |
| Tigecycline for Injection | 50mg*10 phials in each box | Pfizer Europe MA EEIG (Wyeth Lederle
S.r.l.) |
415.90 yuan/box |
Since 2018, China National Healthcare Security Administration (NHSA) has organized 7 rounds of VBPs which cover 294 drugs (differentiated by active ingredients). According to the estimation based on pre-VBP prices, drugs in the VBPs account for 35% of the chemical drugs and biological products procured by public medical institutions.
Reprinted from: ChemLinked
Reference Links
China Announces Final Result of the 7th Volume-based Procurement (VBP) for Drugs
China Kicks off the 7th Round of Volume-based Procurement (VBP) of Drugs
More news on pharmaceutical regulations
Contact Us
BaiPharm, a subsidiary of REACH24H Consulting Group, is specialized in pharmaceutical industry consultancy services. With our experts across China, Japan, South Korea, the United States, and Europe, BaiPharm is fully qualified to engage in complex market entry projects of finished drugs, APIs, excipients, and packaging materials for most key markets.
If you have any questions about pharmaceutical regulatory compliance in China, please feel free to contact us.
Tel: +86 (0)571-87007555
Email: customer@reach24h.com
